Name | Title | Contact Details |
---|---|---|
Jason Rutherford |
Director of Information Technology and | Profile |
Gwendolyn Binder |
Executive Vice President of Science and Technology | Profile |
Gwendolyn Binder |
President of Science and Technology | Profile |
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
Trisand Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
Ostioporsis Imaging Ctr/Breast is a Palm Harbor, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.